AVEO Pharmaceuticals Inc., a Cambridge, Mass.-based oncology drug company, raised around $81 million via its IPO. The company priced nine million shares at $9 per share, compared to plans to sell seven million shares at between $13 and $15 per share.
The company will trade on the Nasdaq under ticker symbol AVEO, while J.P. Morgan and Morgan Stanley served as co-lead underwriters.
Read more »